

Introducing Synoglide™: a First-of-its-Kind OA Microparticle Hydrogel

Shirley, New York – December 3, 2025 – American Regent® Animal Health, the makers of Adequan i.m.® (polysulfated glycosaminoglycan), in partnership with Allegro, unveils Synoglide™, a step forward in intra-articular hydrogel therapy. Engineered to behave like biology, Synoglide is a compelling new veterinary device for treating equine osteoarthritis using nanotechnology. In a clinical study of 29 horses, 89.6% experienced a reduction in lameness 4 weeks after treatment, with 72.4% experiencing complete resolution of lameness.¹

Allegro CEO and President, Lucas Decuypere, will present the technology behind Synoglide during the annual American Association of Equine Practitioners conference on Tuesday, December 9, from 12-12:30 MST in Theater One on the show floor. This announcement comes just one year after Allegro introduced the innovative hydrogel technology concept at AAEP in 2024. Decuypere will be available for questions after the presentation.

Using dynamic, self-healing microparticle technology and derived from natural ingredients, Synoglide was clinically shown to help restore biomechanics for improved joint function. Once injected into the joint, Synoglide's cross-linked microparticle bonds are designed to strengthen under mechanical stress, providing extra support when the joint works the hardest. Biodegradable, mechanically responsive and designed to enhance the body's natural synovial fluid, Synoglide provides protection that performs under pressure.

"We are excited at the potential this device offers to equine athletes, veterinarians and horse owners as a valuable addition to the treatment continuum for osteoarthritis in horses. Synoglide ushers in a fresh perspective on how we address arthritis, reduce discomfort, and help restore movement with intra-articular care. Designed to mimic both the elasticity and rheopectic behavior of synovial fluid, Synoglide has the potential to shift how the industry views intra-articular therapy. We look forward to seeing the impact this product will have on the well-being of our equine partners," said Andy Ferrigno, Senior Director, International Sales & Marketing, American Regent Animal Health.

American Regent Animal Health is the maker of Adequan i.m. and Adequan Canine, FDA-approved polysulfated glycosaminoglycan products for horses and dogs that treat osteoarthritis. For more than 40 years, American Regent Animal Health has proudly delivered solutions that support the long-term health and well-being of horses and dogs.

Allegro is a biomedical company developing transformative nanotechnology-based treatments for degenerative joint disease. Under the agreement, Allegro will manufacture Synoglide in its recently opened state-of-the art cleanroom facility which has a current annual capacity of a million syringes per year.

Veterinarians are encouraged to contact an American Regent Animal Health representative at 1-800-458-0163 to sign up to receive a sample of Synoglide when product becomes available in early 2026.

Media should contact Kyla Jones at Kyla.jones@fwdpeople.com for more information about the launch.

American Regent Inc.® (www.americanregent.com), a Daiichi Sankyo Group company, is an industry-leading injectable manufacturer. For over 50 years, American Regent has been developing, manufacturing, and supplying quality generic and branded injectables for healthcare providers. Our animal health business has proudly delivered solutions that support the long-term health and well-being of horses and dogs, anchored by two of the leading animal joint health brands.

Allegro NV is a private biomedical company developing transformative treatments for degenerative joint diseases based on its proprietary nanotechnology platform, INTRICATE. The company's lead product candidate, Hydrocelin, is a first-in-class, potentially disease-modifying medical device candidate for the treatment of osteoarthritis. Allegro is preparing to initiate human clinical studies of Hydrocelin in 2026. Synoglide™, a veterinary formulation of Hydrocelin, is partnered with American Regent®, a subsidiary of Daiichi Sankyo, for further development and global commercialization, excluding the Middle-East.

Synoglide™ is indicated for intra-articular injection for the management of non-infectious causes of osteoarthritis in horses. Federal law restricts this device to sale by or on the order of a licensed veterinarian. As with any intra-articular procedure, infection risk exists. Use strict aseptic technique.

Adequan® i.m. polysulfated glycosaminoglycan (PSGAG) solution 100 mg/mL

INDICATIONS

Adequan® i.m. is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.

IMPORTANT SAFETY INFORMATION

There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan (PSGAG). **WARNING:** Do not use in horses intended for human consumption. **CAUTION:** Federal law restricts this drug to use by or on the order of a licensed veterinarian. For additional safety information, please see [full prescribing information](#) at [adequan.com](#)

Adequan® Canine polysulfated glycosaminoglycan (PSGAG) solution 100 mg/mL

INDICATIONS AND USAGE

Adequan® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.

IMPORTANT SAFETY INFORMATION

Adequan® Canine should not be used in dogs who are hypersensitive to polysulfated glycosaminoglycan (PSGAG) or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea, and abnormal bleeding) were mild and self-limiting. In post approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy and diarrhea have also been reported. The safe use of PSGAG in breeding, pregnant or lactating dogs has not been evaluated. **Caution:** Federal law restricts this drug to use by or on the order of a licensed veterinarian. For additional safety information, please see [full prescribing information](#) at [adequancanine.com](#).

¹An unblinded study of 29 mature thoroughbreds with lameness assessed on the AAEP scale at 1-4 out of 5 due to OA and confirmed with radiographs (hocks and fetlocks). Data on File.